Press Release

<< Back

November 4, 2021 at 4:05 PM EDT

iRhythm Technologies Announces Third Quarter 2021 Financial Results

SAN FRANCISCO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three months ended September 30, 2021.

Third Quarter 2021 Financial Highlights

  • Revenue was $85.4 million, a 18.7% increase compared to third quarter 2020
  • Gross margin was 65.7%, a 8.9% decrease compared to third quarter 2020
  • Adjusted EBITDA (defined as EBITDA less stock compensation) was negative $8.7 million
  • Cash and Short-Term Investments were $256.8 million as of September 30, 2021, a $1.1 million increase from June 30, 2021

"Our third quarter results reflect the continued strength of our Zio platform with further market penetration of Zio XT in the U.S. complemented by strong growth from Zio AT and in the U.K.,” commented Quentin Blackford, iRhythm's President and CEO. “Once again, strong volume growth offset Medicare pricing headwinds. Further, despite the impact of staffing shortages which reduced volumes and impacted iRhythm’s ability to onboard new accounts, the company achieved 19% year-over-year growth and made tremendous progress working through clinical backlog to bring turnaround times back to normal levels.   While staffing shortages remain a headwind, we have now resumed full sales activities and are encouraged by our registration trends as we have entered the fourth quarter."

Operational Highlights

  • Appointed Quentin Blackford President and CEO
  • Appointed Karen Ling to Board of Directors, replacing Raymond Scott, who retired
  • 3-year results from the mHealth Screening to Prevent Strokes (mSToPS) clinical trial published in PLOS One
  • Surpassed two significant service delivery milestones that included serving four million patients in our history and amassing over one billion hours of curated ECG data
  • Received a UCSF Health Award in the Remote Diagnostic Tool category

“In just the few short weeks that I have been a part of the iRhythm team, I've gained an even deeper appreciation of the value that the Zio platform can bring to patients, physicians, and the healthcare system. It is clear to me that our clinical and competitive differentiation is widely recognized, and the Zio service is seen as best in class,” added Blackford. “Looking ahead, I see significant opportunity for continued growth in the U.S., expansion into the Silent AF market and international development. To capture our full potential, we must also transform the way that we operate so we can scale our business effectively and efficiently. I am very excited to be a part of this dedicated team of professionals as we further build on our world-class commercial and innovation capabilities while achieving new levels of operational excellence."

Medicare Reimbursement Update
On November 2, 2021, the Centers for Medicare and Medicaid Services (CMS) released the Calendar Year 2022 Medicare Physician Fee Schedule (MPFS) Final Rule and accompanying Addenda, along with updated payment policies, payment rates, and other provisions for services furnished under MPFS on or after January 1, 2022. In the Final Rule, CMS did not issue national pricing and continued carrier pricing for calendar year 2022 on Category I CPT codes 93241, 93243, 93245 and 93247 for extended external ECG monitoring, the relevant codes for the Zio XT service.

iRhythm and other industry participants have been working with Medicare Administrative Contractors (MACs) to establish pricing for these codes. iRhythm remains engaged with all of the MACs and is working with other industry participants to submit additional cost data on long-term continuous ECG monitoring for consideration to establish fair and appropriate local rates. iRhythm is evaluating the new information included in the Final Rule and its potential implications on discussions with the MACs. iRhythm cannot provide certainty at this time on the potential outcome of the discussions with the MACs or on the timing of any action to be taken.

Third Quarter Financial Results
Revenue for the three months ended September 30, 2021 increased 18.7% to $85.4 million, from $71.9 million during the same period in 2020. The increase was driven by an increase in volume partially offset by a decrease in Zio XT Medicare reimbursement rates.

Gross profit for the third quarter of 2021 was $56.1 million, up from $53.7 million during the same period in 2020, while gross margins were 65.7%, down from 74.7% during the same period in 2020. The decrease in gross margin was primarily due to a decrease in Zio XT Medicare reimbursement rates, and higher costs related to ensuring clinical capacity.

Operating expenses for the third quarter of 2021 were $79.4 million, compared to $58.5 million for the same period in 2020. The increase in operating expenses was primarily due to increases in compensation and legal spending.

Net loss for the third quarter of 2021 was $23.7 million, or a loss of $0.81 per share, compared with net loss of $4.7 million, or a loss of $0.17 per share, for the same period in 2020.

Financial Guidance
Based on unforeseen ongoing impacts from the COVID-19 Delta variant, customer staffing challenges and delayed new account launches and expansion, iRhythm expects revenue to range from $317 million to $319 million for the full year 2021, representing year over year growth of approximately 20%. This compares to previous revenue guidance of $320 million to $325 million.

Webcast and Conference Call Information
iRhythm’s management team will host a conference call today beginning at 1:30 p.m. PT/ 4:30 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and archived webcast of the event available on the “Investors” section of the company’s website at:

About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.

Use of Non-GAAP Financial Measures and Other Operating Metrics
We refer to certain financial measures that are not recognized under U.S. generally accepted accounting principles ("GAAP") in this press release, including: Adjusted EBITDA. See the schedules to this press release for additional information and reconciliations of such non-GAAP financial measures.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include statements relating to reimbursement rates and coverage, market expansion, plans to reduce costs and improve efficiency, expectations for future performance and financial guidance. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission on Forms 10-K and 10-Q. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.

Investor Relations Contact:
Leigh Salvo
(415) 937-5404 
Media Contact:
Morgan Mathis


Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)

  September 30,
  December 31,
Current assets:      
Cash and cash equivalents $ 167,371     $ 88,628  
Short-term investments 89,396     246,589  
Accounts receivable, net 52,820     29,932  
Inventory 9,960     5,313  
Prepaid expenses and other current assets 5,641     7,363  
Total current assets 325,188     377,825  
Property and equipment, net 53,429     34,247  
Operating lease right-of-use assets 86,116     84,714  
Goodwill 862     862  
Other assets 14,655     14,091  
Total assets $ 480,250     $ 511,739  
Liabilities and Stockholders’ Equity      
Current liabilities:      
Accounts payable $ 4,893     $ 4,365  
Accrued liabilities 53,141     40,532  
Deferred revenue 2,374     930  
Debt, current portion 11,667     11,667  
Operating lease liabilities, current portion 10,707     8,171  
Total current liabilities 82,782     65,665  
Debt, noncurrent portion 12,603     21,339  
Other noncurrent liabilities 2,432     1,830  
Operating lease liabilities, noncurrent portion 86,593     81,293  
Total liabilities 184,410     170,127  
Stockholders’ equity:      
Preferred stock —      —   
Common stock 27     27  
Additional paid-in capital 669,373     646,258  
Accumulated other comprehensive income (6 )   11  
Accumulated deficit (373,554 )   (304,684 )
Total stockholders’ equity 295,840     341,612  
Total liabilities and stockholders’ equity $ 480,250     $ 511,739  


Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)

  Three Months Ended
September 30,
  Nine Months Ended
September 30, 2021
  2021   2020   2021   2020
Revenue, net $ 85,432     $ 71,944     $ 241,021     $ 186,357  
Cost of revenue 29,284     18,232     78,737     49,779  
Gross profit 56,148     53,712     162,284     136,578  
Operating expenses:              
Research and development 8,685     8,768     26,801     29,725  
Selling, general and administrative 70,745     49,701     203,227     140,945  
Total operating expenses 79,430     58,469     230,028     170,670  
Loss from operations (23,282 )   (4,757 )   (67,744 )   (34,092 )
Interest expense (279 )   (384 )   (921 )   (1,145 )
Other income, net (76 )   569     103     1,311  
Loss before income taxes (23,637 )   (4,572 )   (68,562 )   (33,926 )
Income tax provision 94     105     308     253  
Net loss $ (23,731 )   $ (4,677 )   $ (68,870 )   $ (34,179 )
Net loss per common share, basic and diluted $ (0.81 )   $ (0.17 )   $ (2.35 )   $ (1.25 )
Weighted-average shares, basic and diluted 29,433,003     28,050,210     29,294,559     27,358,096  


Reconciliation of Net Loss to Adjusted EBITDA
(In thousands)

  Three Months Ended September 30,   Nine Months Ended
September 30, 2021
  2021   2020   2021   2020
Net loss $ (23,731 )   $ (4,677 )   $ (68,870 )   $ (34,179 )
Income tax provision 94     105     308     253  
Depreciation and Amortization 2,549     1,700     6,738     4,922  
Interest expense 223     223     717     163  
Stock-based compensation 12,160     17,444     42,651     27,517  
Adjusted EBITDA $ (8,705 )   $ 14,795     $ (18,456 )   $ (1,324 )

Primary Logo